Advanced hemostatic adhesive hydrogel system for postpartum hemorrhage control
Active Grant Awarded
- Award ID
- R44HL184761
- Recipient
-
Limax Biosciences Inc. UEI QFMAHRKBJMH2
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,047,908
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 10% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Heart, Lung, and Blood Institute, awarded Limax Biosciences Inc. a grant obligating $1.047908 million on September 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds the R44 study to perform the key advanced biocompatibility and large animal GLP trials required for a 510(k) submission for HEMOMAX-PPH, a biodegradable hydrogel adhesive for postpartum hemorrhage control, as a Class II device. Three activities are funded: bench performance evaluation of final packaged and sterilized HEMOMAX-PPH, ISO 10993 biocompatibility testing for the FDA submission, and a large animal GLP acute and chronic trial as part of the 510(k) regulatory package. The source states that further development is essential to achieve FDA approval and commercial readiness as a vascular sealant. The period of performance runs from the award date to the ultimate completion date of August 31, 2028. Place of performance is Boston, MA 02115.
Description
- Abstract
- Postpartum hemorrhage (PPH) is the leading common cause of maternal mortality worldwide. Despite the availability of several balloon tamponade and vacuum-based products, over 287,000 women DIE from complications of pregnancy and childbirth each year, with mortality rates in low-income countries >35X that of first world countries.1 existing technologies are limited to mechanical tamponade and fail to address the underlying hemostatic dysfunction essential for effective PPH management. Limax biosciences, INC. Addresses this urgent need with hemomax-PPH, a biodegradable hydrogel adhesive that combiens strong adhesion energies 100 to 1,000 times greater on wet surfaces than existing sealants with a balloon tamponade and negative pressure system to combat PPH. This innovative material forms a durable seal within minutes, irrespective of blood exposure, and accommodates in vivo dynamics, as demonstrated by in vitro and in vivo studies. These studies highlight hemomax-PPH's potential to address PPH. While these promising results establish its efficacy, further development is essential to achieve FDA approval and commercial readiness as a vascular sealant, paving the way for widespread clinical impact. The overall objective of this R44 study is to perform key advanced biocompatibility and large animal GLP trials required towards a 510(K) for hemomax-PPH as a class II device. This project will: (1) evaluate bench performance of final packaged and sterilized hemomax-PPH, (2) conduct ISO10993 testing for advanced biocompatibility evaluation part of FDA submission, (3) conduct a large animal GLP acute and chronic trial as part of 510(K) regulatory submission package. The demonstration of safety and efficacy of hemomax-PPH will bring about a paradigm shift in the management of bleeding in PPH. Together, this funding will enable limax biosciences to support its data package towards a 510(K) for hemomax-PPH.
Quick answers
Who received award R44HL184761?
R44HL184761 was awarded to Limax Biosciences Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R44HL184761 worth?
$1,047,908 has been obligated on R44HL184761.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award